Minocycline is currently approved in the US for the treatment of infections caused by susceptible isolates of Acinetobacter spp. The objective of these studies was to determine the minocycline exposures associated with antibacterial effect against A. baumannii in a rat pneumonia model. Rats received minocycline doses as 30 minute intravenous infusions. In the rat pneumonia model, six clinical isolates of A. baumannii, with MICs ranging between 0.03 - 4 mg/L, were studied. In this model, minocycline produced a bacteriostatic effect with a free 24h AUC/MIC of 10 – 16 and produced 1-log of bacterial killing with a free 24h AUC/MIC of 13 – 24. These exposures can be achieved with the current FDA approved dosage regimens of IV minocycline.
https://ift.tt/2QtNIPi
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου